MAP2K7 and metastatic melanoma: Furthermore, the combination of the BRAF inhibitor, vemurafenib, and the MEK inhibitor, cobimetinib, also provided a significant benefit compared to vemurafenib alone [210], suggesting that dual targeting may provide better clinical outcomes for metastatic melanoma.